SCHEMBL891166

SCHEMBL891166

CCCCCOC(=O)Nc1ccn([C@]2(O)O[C@H](CO)[C@@H](O)[C@@]2(C)O)c(=O)n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.40
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
ALDH1A1 P00352 2/20 0.33
PKM P14618 1/20 0.33
POLB P06746 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
CSNK2A2 P19784 1/20 0.32
CSNK2A1 P68400 1/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MAPT P10636 1/20 0.32
CYP1A2 P05177 1/20 0.32
NFKB1 P19838 1/20 0.32
CYP2C19 P33261 1/20 0.32
STAT1 P42224 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL891694 0.91 LMNA (0.38) LMNAPRMT5WDR77ALDH1A1PKM
SCHEMBL891962 0.91 LMNA (0.38) LMNAPRMT5WDR77ALDH1A1PKM
SCHEMBL891439 0.90 POLB (0.35) POLBNPC1RAB9ASMN1; SMN2MAPT
SCHEMBL891938 0.90 LMNA (0.36) LMNAPRMT5WDR77ALDH1A1PKM
SCHEMBL891584 0.90 LMNA (0.36) LMNAPRMT5WDR77ALDH1A1PKM
SCHEMBL891602 0.89 POLB (0.34) POLB
SCHEMBL891732 0.88 BCHE (0.38) ALDH1A1POLBMAPT
SCHEMBL891674 0.87 POLB (0.33) POLB
SCHEMBL891685 0.85 POLB (0.34) POLB
SCHEMBL891474 0.85 POLB (0.33) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120082645-A1 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF XENOPORT, INC. (US) 2012-04-05 US claimed
US-8058260-B2 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof XENOPORT, INC. (US) 2011-11-15 US claimed
US-20070270374-A1 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof XENOPORT, INC. 2007-11-22 US claimed
US-20120082645-A1 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF XENOPORT, INC. (US) 2012-04-05 US disclosed
US-8058260-B2 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof XENOPORT, INC. (US) 2011-11-15 US disclosed
US-20070270374-A1 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof XENOPORT, INC. 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120082645-A1 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MTAP, NSUN2, CDA LMNA 1243/4885PRMT5 123/4885WDR77 790/4885
US-20070270374-A1 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof MTAP, NSUN2, PAICS LMNA 1214/4885PRMT5 130/4885WDR77 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.